Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Set Alert for Articles By Brian Yang

Latest From Brian Yang

China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene

After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for  Celgene's Abraxane to supply China.

Manufacturing Compliance

Coronavirus Clash: Global Pharma Scrambles In Locking Down World

A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.

Coronavirus COVID-19 Business Strategies

China Clears First Coronavirus Vaccine Trial

Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.

Coronavirus COVID-19 Clinical Trials

Race On: China Starts Coronavirus Vaccine Trial, Vows Fast Development

Leveraging on its Ebola vaccine success, Tianjin-based CanSino is testing its vaccine on humans in Wuhan and hopes to get China’s first COVID-19 vaccine on the market soon.

Research & Development Coronavirus COVID-19

From Biogen To Bayer: Coronavirus A Stress Test For Pharma

When a global pandemic hits and local rules over personal movement are highly fluid and constantly updated, two pharma firms with a global footprint have faced unprecedented tests.

Coronavirus COVID-19 China

Some Caution Over 'People’s Hope' Remdesivir As China Trials Progress

Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.

Coronavirus COVID-19 Clinical Trials
See All
UsernamePublicRestriction

Register